Purchase this article with an account.
Y. Kimura; Trans–Tenon's Retrobulbar Triamcinolone Injection for Central Retinal Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2005;46(13):493.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To assess the efficacy of trans–Tenon’s retrobulbar triamcinolone injection for central retinal vein occlusion ( CRVO ) . Methods: Thirteen eyes of 13 patients ( 5 men and 8 women) with CRVO were included. Patient’s age ranged from 38 to 83 years ( average, 66). The follow–up periods were 3 to 12 months (average 7). Patients were treated with trans–Tenon’s retrobulbar injection of 20 mg triamcinolone acetonide. Macular edema was monitored by optical coherence tomography (OCT). Trans–Tenon’s injection was repeated for one to 7 times (average 3.7) in each eye with mean interval of 1.5 months. Results: Visual acuity of all eyes was improved from 0.905 logMAR at baseline to 0.715 logMAR at 1 month, and 0.679 logMAR at 2 month after injection, and 0.764 logMAR at final. Seven patients had visual improvement with more than 2 lines and their final visual acuity was 20/40 or better. Retinal hemorrhage decreased in 10 patients ( 77% ). OCT revealed resolution of macular edema in 11 ( 85% ) of 13 eyes. Eight of the 11 eyes restored normal foveal configuration. However 5 of the 11 eyes with resolved macular edema developed recurrence of macular edema. Slight elevation of intraocular pressure was noted in 4 patients but they did not need medication. Efficacy of the injection decreased after third session. Conclusions: Trans–Tenon’s retrobulbar injection of triamcinolone was effective to reduce macular edema and retinal hemorrhage in CRVO. Macular edema recurred despite the repeated injection.
This PDF is available to Subscribers Only